T-CiRA A joint program between Takeda and Center for iPS Cell Research and Application (CiRA)  that will change the future of medicine using iPS cells

Izumo Seigo Global Head of
Regenerative Medicine Unit of Shonan Research center

Shinya Yamanaka Director of Center for
iPS Cell Research and Application (CiRA), Kyoto University

T-CiRA A joint program between Takeda and Center for iPS Cell Research and Application (CiRA)  that will change the future of medicine using iPS cells
T-CiRA A joint program between Takeda and Center for iPS Cell Research and Application (CiRA)  that will change the future of medicine using iPS cells
T-CiRA A joint program between Takeda and Center for iPS Cell Research and Application (CiRA)  that will change the future of medicine using iPS cells

NEW

November 24, 2016
"T-CiRA Brochure" has been updated.

T-CiRA

This visual symbolizes the nature of this joint program.
The four colors, red, blue, green and black - applied in the visual symbolize the four defined factors CiRA used when first inducing iPS cells, as well as interaction among patients, researchers, clinicians and iPS cells. The red is not only one of CiRA's image color but is also Takeda's symbol color.

The center of the emblem is a paper crane, which in Japan, represents hopes and prayers for patients. We hope to deliver innovative medicines to patients as quickly as possible. The tri-colored circle surrounding the crane represents T-CiRA striving toward drug discovery through clinical applications of basic research of iPS through diversified projects, as a one team.

T-CiRA Joint Program

Collaborative research aiming to develop
innovative treatments over a 10-year period

T-CiRA is a joint research program by the Center for iPS Cell Research and Application (CiRA), Kyoto University and Takeda Pharmaceutical Company Limited. Over a 10-year period and under the direction of CiRA, this joint program will conduct research to develop clinical applications of iPS cells. We aim to develop innovative drugs and cell treatments in such areas as heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases in order to fulfill the needs of patients promptly.

Professor Shinya Yamanaka Director of Center for iPS Cell Research and Application (CiRA), Kyoto University

"This 10-year joint program with Takeda, Japan's largest pharmaceutical company, will become a powerful engine to realize medical applications using iPS cells," said Yamanaka. "We sincerely thank Takeda's commitment to iPS cell research. This partnership will contribute to the development of new therapies to cure not only major diseases but also rare ones."

Christophe Weber Representative Director, President & CEO, Takeda

"I am excited that we will be able to collaborate with CiRA, the world's leading institute dedicated to pioneering iPS cell research," said Christophe Weber, President, and Chief Executive Officer of Takeda. "Through this partnership, our company will provide significant assistance over a long period to CiRA's research into iPS cell technology applications, which is a vital part of Japan Revitalization Strategy. It is our hope to deliver innovative treatments that meet patient needs as soon as possible through this collaboration between Takeda and CiRA."

T-CiRA (Takeda-CiRA) Joint Program Framework

  • Leader: Professor Shinya Yamanaka (Director of CiRA)
  • Goal: Develop clinical application of induced pluripotent stem (iPS) cells
  • Areas: Heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases, etc.
  • Takeda

    • To provide collaborative funding of 20 billion yen over a 10-year period
    • To provide more than 12 billion yen worth of research support
    • To provide R&D know-how
    • To provide research facilities at Shonan Research Center
    • To provide platform for drug development
    • To provide access to compound libraries
    • To provide researchers
  • CiRA

    • To direct the research program
    • To provide iPS cell technologies
    • To provide drug development targets and assay systems
    • To provide principle investigators, researchers and postdoctoral fellows
  • Shonan Research Center

    A global research center, created by merging the Osaka and Tsukuba Research Centers, helps accelerate innovations in drug development. Here, approximately 1,200 researchers conduct non-clinical research from the early stages of the R&D process such as drug targeting and compound candidate selection to placing drugs on the market.

Cell Therapies
Disease Models
Medicines

The Research

Cutting-edge research towards the clinical
application of iPS cells

Center for iPS Cell Research and Application (CiRA) will possibly bring on breakthrough changes to the future of medicine including the research and development of new drugs, cell therapies and drug safety evaluation processes. T-CiRA will conduct cutting-edge research towards the clinical application of iPS cells in areas such as heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases at Takeda's Shonan Research Center.

Research to be conducted by T-CiRA

Main Areas of Research

  • Research towards the clinical application of iPS cells for heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases, etc.
  • Research to develop medicines and cell therapies using iPS cells.

Project Details

  • Akitsu Hotta (PI)
    Naoto Inukai (Sub PI from Takeda)
    Genome Editing Gene Therapy for Congenital Muscular Dystrophy:
    For targeting severe muscular dystrophy caused by a genetic mutation, Dr. Hotta’s team aims to correct the causal genetic mutation using the latest genome editing technologies. While investigating efficacy and safety in patient-derived iPS cells, they will strive to develop a novel gene therapy for patients.
  • Haruhisa Inoue (PI)
    Takeshi Niki (Sub PI from CiRA)
    Takeshi Hioki (Sub PI from Takeda)
    ALS drug discovery and development using patient-derived iPSCs:
    The aim of the project is to develop new therapeutic drugs for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder, using patient derived iPSCs and Takeda's compounds or drug libraries.
  • Hidetoshi Sakurai (PI)
    Yuko Kokubu (Sub PI from CiRA)
    Tomoya Uchimura (Sub PI from CiRA)
    Tomoko Nagino (Sub PI from Takeda)
    Masahiro Oka (Sub PI from Takeda)
    Drug discovery for intractable muscular disease through patient-derived iPSCs:
    Dr. Sakurai's team aims to create new therapeutic drugs for treating intractable muscular diseases, such as muscular dystrophy. To achieve this goal, they will utilize patient-derived iPSCs as a tool for disease modeling and drug screening.
  • Makoto Ikeya (PI)
    Daisuke Kamiya (Sub PI from CiRA)
    Yasuhiro Tsukimi (Sub PI from Takeda)
    A new research platform with human iPSC-derived neural crest cells and its application for drug discovery and regenerative medicine:
    Neural crest cells differentiate into diverse lineages of cell types such as cranial bones or peripheral neurons, which suggest their great potential in clinical application. Dr. Ikeya’s team’s aims are 1) to establish the robust methods for generating iPSC-derived neural crest stem cells and subsequent post-mitotic cell types, and 2) to apply those platforms to drug discovery and regenerative medicine through the development of cellular (disease) models in combination with cutting-edge technologies.
  • Shin Kaneko (PI)
    Yuta Mishima (Sub PI from CiRA)
    Akira Hayashi (Sub PI from Takeda)
    Yoshiaki Kassai (Sub PI from Takeda)
    Development of a novel immuno-cell therapy by iPSC-derived cancer antigen-specific cytotoxic T lymphocytes:
    Dr. Kaneko's team is developing new cancer immuno-cell therapy drugs using iPSC technology. In addition, the combination of the iPS cell stock at CiRA and Takeda's experience in drug development allows the team to investigate practical applications of advanced regenerative medicine for cancer treatment.
  • Takanori Takebe (PI)
    Masaru Koido (Sub PI from Yokohama City University)
    Miniature liver technology as a platform for research towards pharmaceutical applications:
    Based on human iPSC-derived miniature liver generation technology developed at Yokohama City University, Dr. Takebe's team is developing an innovative system that can recreate the complex phenomena found within patients' bodies. This research will facilitate investigation into new therapeutic drugs for intractable diseases and a novel predictive platform for detecting rare adverse events that were previously unforeseen with traditional drug discovery research. Dr. Takebe's team aims to create a brand new drug discovery architecture.
  • Taro Toyoda (PI)
    Yutaka Tanoue (Sub PI from Takeda)
    Ryou Itou (Sub PI from Takeda)
    iPS cell technology-based cell therapy for type 1 diabetes:
    Dr. Toyoda's team seeks to develop cell therapy against type 1 diabetes by transplanting iPSC-derived pancreatic cells.
  • Yoshinori Yoshida (PI)
    Kenji Miki (Sub PI from CiRA)
    Norihisa Tamura (Sub PI from Takeda)
    Kenichi Imahashi (Sub PI from Takeda)
    Development of drug discovery platform for heart disease using iPS cells and its application to new therapeutic modalities against heart failure:
    Dr. Yoshida's research team aims to develop next generation platforms for drug discovery using iPSC-derived cardiac cells. It takes full advantage of new technologies including the microRNA-switch developed at CiRA. The team is currently developing effective methods to obtain stage- and subtype-specific cardiac cells from human iPSCs, which will drastically facilitates their biomedical applications. The team's two primary goals are to make it possible to treat heart failure using iPSC-derived cardiac cells and to discover new drugs for heart disease.

Putting the Promise of iPS Cells into Clinical Practice

Induced pluripotent stem (iPS) cells can differentiate into a variety of cell types
  • β-cell (Pancreas)
  • T-cell (Immune system)
  • Cardiomyocyte (Heart)
  • Neuron (Nervous system)
  • Skeletal muscle cell(skeletal muscle)
  • Hepatocyte (Liver)
  • Neural crest cell

Career Opportunities

Come and change the future of medicine with us

T-CiRA recruits researchers that will change the future of medicine using iPS cells with us.

Takeda and CiRA will each recruit 50 researchers (100 researchers in total) from around the world to conduct research at Shonan Research Center.

We are seeking proposals of new research challenges (projects), and principle investigators (Program-Specific faculty of Kyoto University) who will lead the projects to the accomplishment. The principle investigators are desired to form their own research teams with researchers/research assistants who will support the projects, and to start up and drive forward the projects. Please visit the following CiRA webpage for detailed information on the job.

At first, research will be conducted in areas relating to heart failure, diabetes mellitus, neuro-psychiatric disorders cancer and intractable muscle diseases, but as the project progresses, we expect new areas to be added. When the project is progressing at full speed, we plan to work on approximately 10 projects simultaneously.

Latest News

  • November 24, 2016
    "T-CiRA Brochure" has been updated.
  • November 11, 2016
    "Project Details" have been updated.
  • July 7, 2016
    "Recruiting Advertising" has been updated.
  • May 12, 2016
    Project Details has been updated.
  • March 16, 2016
    "Career Opportunities" has been updated.
  • December 15, 2015
    The special site for T-CiRA has been published.
  • December 15, 2015
    The recruitment process for researchers has begun.

For inquiries regarding T-CiRA

Takeda Pharmaceutical
Company  Limited Shonan Research Center

  • Phone: +81(0)466-32-2111
  • Fax: +81(0)466-29-4405

Email: T_CiRA@takeda.co.jp